DigestiveICD-10: K76.0Affects approximately 25% of the global population

Fatty Liver Disease

Also known as: NAFLD, Non-Alcoholic Fatty Liver Disease, MASLD, Hepatic Steatosis

Fatty liver disease occurs when excess fat accumulates in liver cells, and is the most common liver disorder in developed countries. Non-alcoholic fatty liver disease (NAFLD) can progress to NASH, which involves inflammation and can lead to cirrhosis and liver failure. Lifestyle modifications, particularly weight loss and exercise, are the cornerstone of treatment.

Last updated October 31, 2026

Understanding Fatty Liver Disease

Fatty liver disease means more than 5 percent of your liver's weight is fat, in someone who drinks little or no alcohol. In 2023 the condition was renamed metabolic dysfunction-associated steatotic liver disease (MASLD) to reflect its real cause, and its inflamed, scarring form NASH became MASH, but the older names are still everywhere. It is now the most common liver condition on earth, affecting around 30 percent of adults and up to 70 percent of people with type 2 diabetes. Most people have simple steatosis, fat without much inflammation, which rarely harms the liver itself. About one in five progress to MASH, where ongoing injury lays down scar tissue, and a minority of those reach cirrhosis. Blood tests can be entirely normal at every stage, which is why it is so often found by accident on an ultrasound ordered for something else.

The liver fills with fat because more arrives than it can burn or export. Roughly 60 percent of that fat comes from fat tissue that has become insulin-resistant and leaks fatty acids into the bloodstream, about 25 percent is made fresh in the liver from sugar, particularly fructose, and only around 15 percent comes directly from dietary fat. Fat-laden liver cells become stressed and some die, which summons immune cells and activates the liver's stellate cells to produce collagen. That scarring, measured as fibrosis stage F0 to F4, is the single best predictor of what happens next: people at stage F2 or above face rising rates of liver failure and liver cancer, while those at F0 to F1 mostly do not. The commonest cause of death at every stage, however, is cardiovascular disease, because the same insulin resistance is damaging the arteries.

Simple fatty liver advances slowly, by roughly one fibrosis stage every 14 years on average, while MASH moves about twice as fast and faster still with diabetes. Conventional care begins with staging: a FIB-4 score from routine bloods, then a FibroScan or MRI if that is raised, and occasionally a biopsy. The core treatment is weight loss, and the dose-response is well documented: in a 293-patient study, losing 7 to 10 percent of body weight resolved MASH in 64 percent of people, losing 10 percent or more did so in 90 percent and reversed fibrosis in 45 percent, while losing under 5 percent helped only 10 percent. Beyond that, diabetes and cholesterol are treated aggressively (statins are safe and recommended), GLP-1 drugs and pioglitazone are used off-label, and bariatric surgery resolves MASH in most candidates. Resmetirom, a thyroid-hormone-receptor drug, became the first approved MASH medication in 2024, resolving MASH in about 26 to 30 percent of patients with F2 to F3 fibrosis versus 10 percent on placebo; semaglutide followed in 2025 with MASH resolution in 63 percent versus 34 percent.

Natural approaches have a genuine but limited role here, and the honest ranking puts weight loss, exercise and coffee ahead of every supplement. Vitamin E is the one supplement that made it into liver guidelines: 800 IU daily improved liver histology in 43 percent of non-diabetic adults with biopsy-proven NASH versus 19 percent on placebo, without changing fibrosis, and with safety caveats around prostate cancer and bleeding. Omega-3 lowers liver fat on imaging in meta-analyses without improving inflammation or scarring. Berberine and curcumin reduced liver fat in short Chinese and Iranian trials of low quality, and curcumin products now carry a documented risk of liver injury. Milk thistle, the traditional liver herb, failed its primary endpoint in the best MASH trial. Coffee, two to three cups a day, is associated with about 30 percent less fibrosis in cohort studies and is the cheapest liver-friendly habit there is. Alcohol should be zero: a damaged liver has no safe dose.

The mistake most people make is reassurance from normal liver enzymes. ALT is normal in a large share of people with significant fibrosis, so a normal blood panel does not rule out a problem; a FIB-4 score and, if needed, a FibroScan do. The second mistake is treating 'fatty' as a problem of dietary fat: the fat in the liver is mostly built from excess calories and sugar, so cutting fructose-sweetened drinks and refined carbohydrate does more than cutting olive oil, and the Mediterranean diet, which is relatively high in fat, reduced liver fat by 39 percent in six weeks in one crossover trial. The third is the assumption that a few drinks are fine because the diagnosis says 'non-alcoholic'. Even modest alcohol intake accelerates fibrosis in people with metabolic fatty liver, and the newer classification treats combined metabolic and alcohol-related disease as a distinct, higher-risk category.

At a Glance

Common symptoms
Often asymptomatic in early stages, Fatigue and general weakness, Dull pain or discomfort in the upper right abdomen
Main treatments
Weight loss of 7–10% of body weight through diet and exercise, Mediterranean diet rich in healthy fats, whole grains, and vegetables, Regular aerobic and resistance exercise
Category
Digestive · Affects approximately 25% of the global population
See a doctor if
Blood tests show persistently elevated liver enzymes

Symptoms

Often asymptomatic in early stages
Fatigue and general weakness
Dull pain or discomfort in the upper right abdomen
Unexplained weight loss in advanced stages
Enlarged liver detectable on physical exam
Jaundice in advanced disease
Abdominal swelling from fluid accumulation (ascites)

Causes

  • Insulin resistance and metabolic syndrome
  • Obesity, particularly visceral fat
  • High-sugar and high-fat diets
  • Genetic predisposition (PNPLA3 gene variants)
  • Sedentary lifestyle

Risk Factors

  • Obesity or overweight
  • Type 2 diabetes or prediabetes
  • High cholesterol and triglycerides
  • Metabolic syndrome
  • Polycystic ovary syndrome
  • Obstructive sleep apnea

Diagnosis

  • Blood tests showing elevated liver enzymes (ALT, AST)
  • Abdominal ultrasound revealing fatty infiltration
  • FibroScan (transient elastography) to assess liver stiffness
  • Liver biopsy to confirm NASH and assess fibrosis stage
  • MRI-based techniques for quantifying liver fat

Treatment

  • Weight loss of 7–10% of body weight through diet and exercise
  • Mediterranean diet rich in healthy fats, whole grains, and vegetables
  • Regular aerobic and resistance exercise
  • Management of diabetes, cholesterol, and blood pressure
  • Vitamin E supplementation for non-diabetic NASH patients
  • Emerging therapies such as resmetirom for NASH

Natural remedies for fatty liver disease: what the evidence says

Ranked by the strength of human evidence for fatty liver disease specifically. These sit alongside medical care, not in place of it.

  1. Vitamin E

    Strong evidence

    In the 96-week PIVENS trial, 247 adults with biopsy-proven NASH and no diabetes took 800 IU natural vitamin E, pioglitazone or placebo: vitamin E improved the overall liver histology score in 43 percent versus 19 percent on placebo and lowered liver enzymes, but did not improve fibrosis. In a later trial of 105 people with type 2 diabetes, vitamin E alone did not meet its primary endpoint, so guidelines endorse it only for non-diabetic, non-cirrhotic MASH confirmed on biopsy. It is the only supplement with guideline backing for this condition.

    Studied dose
    800 IU per day of natural (d-alpha or RRR-alpha) tocopherol, as studied, with a meal; reassess liver enzymes and imaging after 6 to 12 months.
    Cautions
    In the SELECT trial, 400 IU daily raised prostate cancer risk by 17 percent, and meta-analyses link high doses to a small rise in hemorrhagic stroke; it increases bleeding with warfarin, aspirin and clopidogrel, so stop two weeks before surgery. Not recommended with diabetes or cirrhosis outside a trial.
  2. Omega-3 (EPA/DHA)

    Moderate evidence

    A 2018 meta-analysis of controlled trials found omega-3 supplements reduced liver fat on imaging and lowered liver enzymes and triglycerides, with doses of 1 to 4 g per day over 6 to 18 months. The two best trials were less encouraging: in the 103-patient WELCOME study, 4 g daily for 15 to 18 months reduced liver fat only in people who stuck with it, and a trial in diabetics with NASH showed no histologic benefit. It helps the fat, not the inflammation or scarring, and it lowers the triglycerides that often accompany fatty liver.

    Studied dose
    2 to 4 g combined EPA and DHA per day with meals for at least six months; prescription-grade concentrates deliver this in fewer capsules.
    Cautions
    High doses raise bleeding risk with anticoagulants and antiplatelets and have increased atrial fibrillation in trials of 4 g per day; stop one week before surgery. Avoid with fish allergy unless using algal oil.
  3. Berberine

    Moderate evidence

    In a 16-week Chinese trial, 184 adults with fatty liver were randomized to lifestyle change alone, lifestyle plus berberine 500 mg three times daily, or lifestyle plus pioglitazone. Berberine reduced liver fat on MR spectroscopy by 52 percent versus 36 percent with lifestyle alone, and improved body weight, insulin resistance and lipids, outperforming pioglitazone on weight. A 2023 meta-analysis of small trials supports lower liver enzymes and liver fat, but no trial has looked at inflammation or fibrosis on biopsy.

    Studied dose
    500 mg two to three times daily with meals (1,000 to 1,500 mg per day), alongside a weight-loss diet, for at least 16 weeks.
    Cautions
    Inhibits CYP3A4, CYP2D6 and P-glycoprotein, raising levels of cyclosporine, simvastatin, metoprolol and others; can lower glucose on top of diabetes drugs. Avoid in pregnancy, breastfeeding and infants (jaundice risk); may cause constipation.
  4. Curcumin

    Moderate evidence

    Two Iranian trials reported large effects: in 77 adults with fatty liver, 500 mg of an amorphous curcumin formulation daily for eight weeks improved ultrasound fat grade in 79 percent versus 28 percent on placebo and lowered liver enzymes; in 87 adults, 1,000 mg curcumin with piperine for eight weeks improved ultrasound findings in 75 percent versus 5 percent. The trials are short, use ultrasound rather than MRI or biopsy, and the effect sizes are implausibly large, so the tier is moderate with reservations.

    Studied dose
    500 to 1,000 mg per day of a bioavailable curcumin preparation with food for eight weeks, with liver enzymes checked before and after.
    Cautions
    Turmeric and curcumin supplements, especially high-dose and piperine-enhanced products, are now a recognized cause of liver injury: the US Drug-Induced Liver Injury Network reported ten cases in 2023, several severe. Stop immediately if ALT rises or jaundice appears. Also avoid with gallstones, bleeding disorders or anticoagulants, and in pregnancy at supplement doses.
  5. Milk Thistle

    Preliminary evidence

    Milk thistle is the traditional liver remedy, but the best trial was negative on its main question. In a 48-week randomized trial, 99 adults with biopsy-proven NASH took silymarin 700 mg three times daily or placebo: the primary endpoint, a 30 percent or greater improvement in the histology score, was reached by 33 percent versus 26 percent, not significant, although fibrosis improved in 22 percent versus 6 percent and liver enzymes fell. A 78-patient US trial of 420 or 700 mg three times daily found no benefit. Meta-analyses show modest ALT reductions only.

    Studied dose
    Standardized silymarin extract 420 to 700 mg three times daily (up to 2,100 mg per day) for 48 weeks, as studied; lower doses have not been tested properly.
    Cautions
    Generally safe; can cause loose stools, and allergic reactions in people sensitive to ragweed and daisies. It may lower blood glucose and mildly inhibit CYP2C9, so monitor with warfarin or phenytoin. Safety in pregnancy is not established.

What matters day to day

  • Lose 7 to 10 percent of body weight, the only intervention proven to resolve MASH: in a 293-patient study it did so in 64 percent at 7 to 10 percent loss and 90 percent at 10 percent or more, with fibrosis reversing in 45 percent of the latter group.
  • Make alcohol zero rather than moderate; even one to two drinks a day is associated with faster fibrosis progression in people with metabolic fatty liver, and there is no evidence of a safe threshold once the liver is already injured.
  • Cut fructose-sweetened drinks and juices first, because the liver turns fructose straight into fat: each daily sugary drink is linked to about 40 to 50 percent higher odds of fatty liver, and restricting fructose reduced liver fat within nine days in children.
  • Exercise 150 to 200 minutes a week; both aerobic and resistance training reduce liver fat by 20 to 30 percent even when weight does not change, because working muscle burns the fatty acids that would otherwise be shipped to the liver.
  • Drink two to three cups of coffee a day if you tolerate it: regular coffee drinkers have roughly 30 percent lower odds of advanced fibrosis in pooled cohort studies, an association seen for caffeinated coffee specifically.
  • Adopt a Mediterranean pattern (olive oil, vegetables, legumes, fish, nuts, little refined grain): in a six-week crossover trial it reduced liver fat by 39 percent versus 7 percent on a standard low-fat diet, without weight loss.

Prevention

  • Maintain a healthy weight
  • Follow a balanced, plant-forward diet
  • Exercise at least 150 minutes per week
  • Limit added sugars and processed foods
  • Avoid excessive alcohol consumption

When to See a Doctor

  • Blood tests show persistently elevated liver enzymes
  • You have risk factors for NAFLD such as obesity or diabetes
  • You experience persistent fatigue or upper abdominal discomfort
  • Yellowing of the skin or eyes develops

Frequently Asked Questions

References

  1. Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). New England Journal of Medicine (2010)View source
  2. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology (2015)View source
  3. Harrison SA, Bedossa P, Guy CD, et al.. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). New England Journal of Medicine (2024)
  4. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology (2023)
  5. Wah Kheong C, Nik Mustapha NR, Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology (2017)
  6. Yan HM, Xia MF, Wang Y, et al.. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One (2015)
  7. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al.. Liver Injury Associated with Turmeric: A Growing Problem. Ten Cases from the Drug-Induced Liver Injury Network. American Journal of Medicine (2023)
  8. Klein EA, Thompson IM, Tangen CM, et al.. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011)View source
  9. Musa-Veloso K, Venditti C, Lee HY, et al.. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutrition Reviews (2018)
  10. National Institute of Diabetes and Digestive and Kidney Diseases. Nonalcoholic Fatty Liver Disease (NAFLD) & NASH: Definition & Facts. NIDDK (2021)View source

Related Conditions

Related from the Supplement Library

These supplements have been studied in relation to Fatty Liver Disease. Always consult your healthcare provider before starting any supplement, especially if you take medications.

Have questions about Fatty Liver Disease?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.